Oncobiologics allies with inVentiv on biosimilars development

Oncobiologics and the CRO inVentiv Health have joined forces to develop a slate of biosimilars. The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux. A variety of new partnerships have been created over the past two years as players position themselves for the arrival of biosimilars, which promise to shave anywhere from 20% to 30% off the cost of some high-profile biologics. At a later point the two partners say their collaboration may be expanded to include novel therapies. FierceCRO article | Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.